Modality
Gene Therapy
MOA
PI3Ki
Target
WEE1
Pathway
Ferroptosis
Ovarian CaCF
Development Pipeline
Preclinical
~Sep 2013
→ ~Dec 2014
Phase 1
~Mar 2015
→ ~Jun 2016
Phase 2
~Sep 2016
→ ~Dec 2017
Phase 3
Mar 2018
→ Dec 2031
Phase 3Current
NCT04763308
1,174 pts·Ovarian Ca
2025-09→2031-12·Terminated
NCT08772356
2,948 pts·Ovarian Ca
2019-08→2029-11·Terminated
NCT08997256
2,303 pts·Ovarian Ca
2025-05→2029-06·Active
+1 more trial
8,286 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2026-08-265mo awayPh3 Readout· Ovarian Ca
2029-06-023.2y awayPh3 Readout· Ovarian Ca
2029-11-213.6y awayPh3 Readout· Ovarian Ca
2031-12-135.7y awayPh3 Readout· Ovarian Ca
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Not yet…
P3
Termina…
P3
Active
P3
Termina…
Catalysts
Ph3 Readout
2026-08-26 · 5mo away
Ovarian Ca
Ph3 Readout
2029-06-02 · 3.2y away
Ovarian Ca
Ph3 Readout
2029-11-21 · 3.6y away
Ovarian Ca
Ph3 Readout
2031-12-13 · 5.7y away
Ovarian Ca
ActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04763308 | Phase 3 | Ovarian Ca | Terminated | 1174 | Mayo |
| NCT08772356 | Phase 3 | Ovarian Ca | Terminated | 2948 | LiverFat |
| NCT08997256 | Phase 3 | Ovarian Ca | Active | 2303 | PFS |
| NCT05968537 | Phase 3 | Ovarian Ca | Not yet recr... | 1861 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 |